CDK4 and glioblastoma: After adjusting for age and gender, GBM patients with mutant CDK4(A)/CDKN2A(D)/RB1 had significantly higher risk for 5-year mortality compared with patients with wild type (HR = 1.837, 95% CI: 1.192–2.831).